Targeting glycogen metabolism in bladder cancer

Nature Reviews Urology

Volumn 12, Issue 7, 2015, Pages 383-391

  Lew, Carolyn Ritterson ^a   Guin, Sunny ^a   Theodorescu, Dan ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4ALPHA GLUCANOTRANSFERASE; ALPHA GLUCOSIDASE; AMYLO 1,6 GLUCOSIDASE; GLYCINE; GLYCOGEN PHOSPHORYLASE; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN; GLYCOGEN;

BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; GLUCOSE METABOLISM; GLYCOGEN METABOLISM; GLYCOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYNTHESIS; METABOLISM; URINARY BLADDER NEOPLASMS;

GLYCOGEN; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84936845786     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.111     Document Type: Review

References (106)

1. Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008
2. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009
3. Dang, C. V., Hamaker, M., Sun, P., Le, A. & Gao, P. Therapeutic targeting of cancer cell metabolism. J. Mol. Med. (Berl.) 89, 205-212 (2011
4. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956
5. Moreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A. & Saavedra, E. Energy metabolism in tumor cells. FEBS J. 274, 1393-1418 (2007
6. Marín-Hernández, A., et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J. 273, 1975-1988 (2006
7. Balinsky, D., Platz, C. E. & Lewis, J. W. Enzyme activities in normal, dysplastic, and cancerous human breast tissues. J. Natl Cancer Inst. 72, 217-224 (1984
8. Stubbs, M., Bashford, C. L. & Griffiths, J. R. Understanding the tumor metabolic phenotype in the genomic era. Curr. Mol. Med. 3, 49-59 (2003
9. Christofk, H. R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008
10. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434 (2006
11. Peng, Q., et al. Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol. Ther. 7, 1128-1135 (2008
12. Ritterson Lew, C. & Tolan, D. R. Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J. Biol. Chem. 287, 42554-42563 (2012
13. Le, A., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037-2042 (2010
14. Clem, B., et al. Small-molecule inhibition of 6 phosphofructo 2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110-120 (2008
15. Biswas, S., Lunec, J & Bartlett, K. Non-glucose metabolism in cancer cells-is it all in the fat? Cancer Metastasis Rev. 31, 689-698 (2012
16. DeBerardinis, R. J., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345-19350 (2007
17. Mashima, T., Seimiya, H. & Tsuruo, T. De novo fatty-Acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100, 1369-1372 (2009
18. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010
19. Linehan, W. M. & Rouault, T. A. Molecular pathways: Fumarate hydratase-deficient kidney cancer-Targeting the Warburg effect in cancer. Clin. Cancer Res. 19, 3345-3352 (2013
20. Adam, J., Yang, M., Soga, T. & Pollard, P. J. Rare insights into cancer biology. Oncogene 33, 2547-2556 (2014
21. Isaacs, J. S., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005
22. Selak, M. A., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85 (2005
23. Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A. & Wu, M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726-734 (2011
24. Hatzivassiliou, G., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321 (2005
25. Milgraum, L. Z., Witters, L. A., Pasternack, G. R. & Kuhajda, F. P. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin. Cancer Res. 3, 2115-2120 (1997
26. Pizer, E. S., et al. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47, 102-110 (2001
27. Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66, 5977-5980 (2006
28. Nomura, D. K., et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61 (2010
29. Yang, C. S., et al. Fatty acid synthase inhibition engages a novel caspase 2 regulatory mechanism to induce ovarian cancer cell death. Oncogene http://dx.doi.org/10.1038/onc.2014.271
30. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
31. Guin, S., et al. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J. Natl Cancer Inst. 106, dju062 (2014
32. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
33. Chang, S., Lee, S., Lee, C., Kim, J. I. & Kim, Y. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology 55, 448-452 (2000
34. Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 202, 654-662 (2005
35. Lee, J. H., Kim, Y. W. & Chang, S. G. Glucose transporter 1 expression in urothelial papilloma of the bladder. Urol. Int. 74, 268-271 (2005
36. Hoskin, P. J., Sibtain, A., Daley, F. M. & Wilson, G. D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 89, 1290-1297 (2003
37. Nagase, Y., et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J. Urol. 153, 798-801 (1995
38. Ozcan, A., Shen, S. S., Zhai, Q. J. & Truong, L. D. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am. J. Clin. Pathol. 128, 245-254 (2007
39. Cushman, S. W. & Wardzala, L. J. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J. Biol. Chem. 255, 4758-4762 (1980
40. Suzuki, K. & Kono, T. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc. Natl Acad. Sci. USA 77, 2542-2545 (1980
41. Gwak, H., Haegeman, G., Tsang, B. K. & Song, Y. S. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Mol. Carcinog. http://dx.doi.org/10.1002/mc.22227
42. Sommermann, T. G., O'Neill, K., Plas, D. R. & Cahir-McFarland, E. IKKβ and NF ?B transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res. 71, 7291-7300 (2011
43. Berg, J. M., Tymoczko, J. L. & Stryer, L. Biochemistry 5th edn (W. H. Freeman, 2002
44. Garrett, R. H. & Grisham, C. M. Biochemistry 2nd edn (Harcourt Brace and Company, 1999
45. Gaboriaud-Kolar, N. & Skaltsounis, A. L. Glycogen phosphorylase inhibitors: a patent review (2008-2012). Expert Opin. Ther. Pat. 23, 1017-1032 (2013
46. Sakoda, H., et al. Glycogen debranching enzyme association with β-subunit regulates AMP-Activated protein kinase activity. Am. J. Physiol. Endocrinol. Metab. 289, E474-E481 (2005
47. Rousset, M., et al. Growth-related enzymatic control of glycogen metabolism in cultured human tumor cells. Cancer Res. 44, 154-160 (1984
48. Rousset, M., Zweibaum, A. & Fogh, J. Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins. Cancer Res. 41, 1165-1170 (1981
49. Pelletier, J., et al. Glycogen synthesis is induced in hypoxia by the hypoxia-inducible factor and promotes cancer cell survival. Front. Oncol. 2, 18 (2012
50. Iida, Y., et al. Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int. J. Oncol. 40, 2122-2130 (2012
51. Pescador, N., et al Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS ONE 5, e9644 (2010
52. Favaro, E., et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell. Metab. 16, 751-764 (2012
53. Philips, K. B., et al. Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2 deoxy d-glucose. Cancer Chemother. Pharmacol. 73, 349-361 (2014
54. Terashima, M., et al. KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. Oncotarget 5, 7040-7050 (2014
55. Gazzerro, E., Andreu, A. L. & Bruno, C. Neuromuscular disorders of glycogen metabolism. Curr. Neurol. Neurosci. Rep. 13, 333 (2013
56. Cheng, A., et al. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev. 21, 2399-2409 (2007
57. Jain, M., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040-1044 (2012
58. Kishnani, P. S., et al. Glycogen storage disease type III diagnosis and management guidelines. Genet. Med. 12, 446-463 (2010
59. Gloeckler Ries, L. A., Reichman, M. E., Lewis, D. R., Hankey, B. F. & Edwards, B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541-552 (2003
60. Johansson, S. L. & Cohen, S. M. Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol. 13, 291-298 (1997
61. Bernier, A. V., et al. Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control. J. Inherit. Metab. Dis. 31, 729-732 (2008
62. Steuerwald, U Health status in GSD3a-patients with a natural high-protein diet. Presented at the International GSD Conference 2013
63. Cosme, A., et al. Type III glycogen storage disease associated with hepatocellular carcinoma [Spanish]. Gastroenterol. Hepatol. 28, 622-625 (2005
64. Demo, E., et al Glycogen storage disease type III hepatocellular carcinoma a long-Term complication? J. Hepatol. 46, 492-498 (2007
65. Haagsma, E. B., et al. Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The Liver Transplant Group. Hepatology 25, 537-540 (1997
66. Labrune, P., Trioche, P., Duvaltier, I., Chevalier, P. & Odièvre, M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J. Pediatr. Gastroenterol. Nutr. 24, 276-279 (1997
67. Siciliano, M., et al. Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J. Clin. Gastroenterol. 31, 80-82 (2000
68. Shimizu, J., et al A report on an adult case of type III glycogenosis with primary liver cancer and liver cirrhosis [Japanese]. Nihon Shokakibyo Gakkai Zasshi 79, 2328-2332 (1982
69. Kishnani, P. S., et al. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. Hum. Mol. Genet. 18, 4781-4790 (2009
70. Calderaro, J., et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J. Hepatol. 58, 350-357 (2013
71. Herrema, H., Smit, G P., Reijngoud, D. J. & Kuipers, F. Does increased fatty acid oxidation enhance development of liver cirrhosis and progression to hepatocellular carcinoma in patients with glycogen storage disease type III? J. Hepatol. 47, 298-300; author reply 300-301 (2007
72. Cimino, G. D., Pan, C. X. & Henderson, P. T. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 5, 369-391 (2013
73. Tsao, C. K., Gartrell, B. A., Oh, W. K. & Galsky, M. D. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev. Anticancer Ther. 12, 1537-1543 (2012
74. Schneider, M., et al. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. Urol. Oncol. 32, 877-884 (2014
75. Bielecka, Z. F., Czarnecka, A. M. & Szczylik, C. Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front. Oncol. 4, 194 (2014
76. Fraser, M., Berlin, A., Bristow, R. G. & van der Kwast, T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol. Oncol. 33, 85-94 (2015
77. Sio, T. T., Ko, J., Gudena, V. K., Verma, N. & Chaudhary, U. B. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review. Int. J. Urol. 21, 630-637 (2014
78. Sternberg, C. N., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur. Urol. 63, 58-66 (2013
79. Hendricksen, K., et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J. Urol. 187, 1195-1199 (2012
80. Schnier, J. B., Nishi, K., Gumerlock, P. H., Gorin, F. A. & Bradbury, E. M. Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer. BMC Urol. 5, 6 (2005
81. Kominsky, D. J., et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR ABL positive cells. Clin. Cancer Res. 15, 3442-3450 (2009
82. Chan, S. S. & Lotspeich, W. D. Comparative effects of phlorizin and phloretin on glucose transport in the cat kidney. Am. J. Physiol. 203, 975-979 (1962
83. Cao, X., et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59, 495-505 (2007
84. Liu, Y., et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther. 11, 1672-1682 (2012
85. Monti, E. & Gariboldi, M. B. HIF 1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr. Mol. Pharmacol. 4, 62-77 (2011
86. Zhao, Y., Butler, E. B. & Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4, e532 (2013
87. Yeung, S. J., Pan, J. & Lee, M. H. Roles of p53, MYC and HIF 1 in regulating glycolysis-The seventh hallmark of cancer. Cell. Mol. Life Sci. 65, 3981-3999 (2008
88. Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006
89. Balar, A. V. & Milowsky, M. I. Cytotoxic and DNA-Targeted therapy in urothelial cancer: have we squeezed the lemon enough? Cancer 121, 179-187 (2015
90. Maschek, G., et al. 2 deoxy d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64, 31-34 (2004
91. Anderson, D. D. & Stover, P. J. SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PLoS ONE 4, e5839 (2009
92. Lee, W. N., et al. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br. J. Cancer 91, 2094-2100 (2004
93. Ma, D., et al. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas 41, 397-408 (2012
94. Schnier, J. B., Nishi, K., Monks, A., Gorin, F. A. & Bradbury, E. M. Inhibition of glycogen phosphorylase (GP) by CP 91, 149 induces growth inhibition correlating with brain GP expression. Biochem. Biophys. Res. Commun. 309, 126-134 (2003
95. Kaiser, A., et al. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys. 386, 179-187 (2001
96. Oikonomakos, N. G., Skamnaki, V. T., Tsitsanou, K. E., Gavalas, N. G. & Johnson, L. N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 8, 575-584 (2000
97. Liu, G., et al. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin. Cancer Res. 10, 924-928 (2004
98. Van Veldhuizen, P. J., et al. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother. Pharmacol. 56, 39-45 (2005
99. Dickson, M. A., et al. A phase I clinical trial of FOLFIRI in combination with the pan cyclin dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother. Pharmacol. 66, 1113-1121 (2010
100. Kaur, G., et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl Cancer Inst. 84, 1736-1740 (1992
101. Pagliarani, S., et al. Glycogen storage disease type III: A novel Agl knockout mouse model. Biochim. Biophys. Acta 1842, 2318-2328 (2014
102. Liu, K. M., Wu, J. Y. & Chen, Y. T. Mouse model of glycogen storage disease type III. Mol. Genet. Metab. 111, 467-476 (2014
103. Newgard, C. B., Hwang, P. K. & Fletterick, R. J. The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem. Mol. Biol. 24, 69-99 (1989
104. McBride, A. & Hardie, D. G. AMP-Activated protein kinase-A sensor of glycogen as well as AMP and ATP? Acta Physiol. (Oxf.) 196, 99-113 (2009
105. Lee, J., Kim, H. K., Han, Y. M. & Kim, J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct 4 in regulating transcription. Int. J. Biochem. Cell Biol. 40, 1043-1054 (2008
106. Funasaka, T., Hogan, V. & Raz, A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res. 69, 5349-5356 (2009